Fragment-based design of kinase inhibitors: A practical guide

Methods in Molecular Biology

Volumn 1289, Issue , 2015, Pages 157-183

  Erickson, Jon A ^a  

^a NONE

Author keywords

Computational chemistry; De novo design; Fragment screening; Fragment based drug design; Kinase inhibitors; Structure based drug design; X Ray crystallography

Indexed keywords

PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; ISOTHERMAL TITRATION CALORIMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SCREENING; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; MOLECULAR LIBRARY; PROCEDURES;

COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES;

EID: 84924212569     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2486-8_13     Document Type: Article

References (84)

1. Fabbro D, Cowan-Jacob SW, Mobitz H, Martiny-Baron G (2012) Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 795:1-34
2. Arencibia JM, Pastor-Flores D, Bauer AF, Schulze JO, Biondi RM (2013) AGC protein kinases: from structural mechanism of regulation to allosteric drug development for the treatment of human diseases. Biochim Biophys Acta 1834:1302-1321
3. Cohen P, Alessi DR (2013) Kinase drug discovery-what's next in the field? ACS Chem Biol 8:96-104
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(1912-1916):1933-1934
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242
6. Breitenlechner CB, Bossemeyer D, Engh RA (2005) Crystallography for protein kinase drug design: PKA and SRC case studies. Biochim Biophys Acta 1754:38-49
7. Chiu Y-Y, Lin C-T, Huang J-W, Hsu K-C, Tseng J-H, You S-R, Yang J-M (2013) KIDFam Map: a database of kinase-inhibitordisease family maps for kinase inhibitor selectivity and binding mechanisms. Nucleic Acids Res 41:D430-D440
8. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP (2008) Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 51:5149-5171
9. Liao JJ-L (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 50:409-424
10. van Linden OP, Kooistra AJ, Leurs R, de Esch IJ, de Graaf C (2014) KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. J Med Chem 57(2):249-277
11. Vieth M, Sutherland JJ, Robertson DH, Campbell RM (2005) Kinomics: characterizing the therapeutically validated kinase space. Drug Discov Today 10:839-846
12. Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R (1993) Phosphotransferase and substrate binding mechanism of the c AMPdependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with manganese(2+) adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J 12:849-859
13. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL, Goldsmith EJ (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure (London) 6:1117-1128
14. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236-4243
15. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534
16. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate-a historical perspective. Drug Discov Today 14:668-675
17. Zartler ER, Shapiro MJ (2005) Fragonomics: fragment-based drug discovery. Curr Opin Chem Biol 9:366-370
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26
19. Congreve M, Carr R, Murray C, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8:876-877
20. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430-431
21. Vieth M, Siegel MG, Higgs RE, Watson IA, Robertson DH, Savin KA, Durst GL, Hipskind PA (2004) Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 47:224-232
22. Saxty G, Woodhead SJ, Berdini V, Davies TG, Verdonk ML, Wyatt PG, Boyle RG, Barford D, Downham R, Garrett MD, Carr RA (2007) Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem 50:2293-2296
23. Verdonk ML, Rees DC (2008) Group effi-ciency: a guideline for hits-to-leads chemistry. Chem Med Chem 3:1179-1180
24. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890
25. Murray CW, Blundell TL (2010) Structural biology in fragment-based drug design. Curr Opin Struct Biol 20:497-507
26. Gradler U, Bomke J, Musil D, Dresing V, Lehmann M, Holzemann G, Greiner H, Esdar C, Krier M, Heinrich T (2013) Fragment-based discovery of focal adhesion kinase inhibitors. Bioorg Med Chem Lett 23:5401-5409
27. Lepre CA (2011) Practical aspects of NMRbased fragment screening. Methods Enzymol 493:219-239
28. Lepre CA, Moore JM, Peng JW (2004) Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev 104:3641-3675
29. Neumann T, Junker HD, Schmidt K, Sekul R (2007) SPR-based fragment screening: advantages and applications. Curr Top Med Chem 7:1630-1642
30. Ladbury JE, Klebe G, Freire E (2010) Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 9:23-27
31. Allen KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, Ringe D (1996) An experimental approach to mapping the binding surfaces of crystalline proteins. J Phys Chem 100:2605-2611
32. Jhoti H, Cleasby A, Verdonk M, Williams G (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11:485-493
33. Davies TG, Tickle IJ (2012) Fragment screening using X-ray crystallography. Top Curr Chem 317:33-59
34. Spurlino JC (2011) Fragment screening purely with protein crystallography. Methods Enzymol 493:321-356
35. Leach AR, Hann MM, Burrows JN, Griffen EJ (2006) Fragment screening: an introduction. Mol Bio Syst 2:429-446
36. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48:403-413
37. Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39:2887-2893
38. Fejzo J, Lepre CA, Peng JW, Bemis GW, Ajay Murcko MA, Moore JM (1999) The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol 6: 755-769
39. Baurin N, Aboul-Ela F, Barril X, Davis B, Drysdale M, Dymock B, Finch H, Fromont C, Richardson C, Simmonite H, Hubbard RE (2004) Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 44:2157-2166
40. Aronov AM, Mc Clain B, Stuver MC, Murcko MA (2008) Kinase-likeness and kinaseprivileged fragments: toward virtual polypharmacology. J Med Chem 51:1214-1222
41. Muegge I, Enyedy IJ (2004) Virtual screening for kinase targets. Curr Med Chem 11:693-707
42. Vieth M, Erickson J, Wang J, Webster Y, Mader M, Higgs R, Watson I (2009) Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. J Med Chem 52: 6456-6466
43. Xia X, Maliski EG, Gallant P, Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463-4470
44. Sutherland JJ, Higgs RE, Watson I, Vieth M (2008) Chemical fragments as foundations for understanding target space and activity prediction. J Med Chem 51:2689-2700
45. Verdonk ML, Giangreco I, Hall RJ, Korb O, Mortenson PN, Murray CW (2011) Docking performance of fragments and druglike compounds. J Med Chem 54:5422-5431
46. Good AC, Liu J, Hirth B, Asmussen G, Xiang Y, Biemann H-P, Bishop KA, Fremgen T, Fitzgerald M, Gladysheva T, Jain A, Jancsics K, Metz M, Papoulis A, Skerlj R, Stepp JD, Wei RR (2012) Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. J Med Chem 55:2641-2648
47. Miranker A, Karplus M (1991) Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins Struct Funct Genet 11:29-34
48. Clark M, Guarnieri F, Shkurko I, Wiseman J (2006) Grand canonical Monte Carlo simulation of ligand-protein binding. J Chem Inf Model 46:231-242
49. Clark M, Meshkat S, Talbot GT, Carnevali P, Wiseman JS (2009) Fragment-based computation of binding free energies by systematic sampling. J Chem Inf Model 49:1901-1913
50. Bohm HJ (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6:61-78
51. Bohm HJ (1992) LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des 6:593-606
52. Eisen MB, Wiley DC, Karplus M, Hubbard RE (1994) HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins Struct Funct Genet 19:199-221
53. Lauri G, Bartlett PA (1994) CAVEAT: a program to facilitate the design of organic molecules. J Comput Aided Mol Des 8:51-66
54. Yang Y, Nesterenko DV, Trump RP, Yamaguchi K, Bartlett PA, Drueckhammer DG (2005) Virtual hydrocarbon and combinatorial databases for use with CAVEAT. J Chem Inf Model 45:1820-1823
55. Maass P, Schulz-Gasch T, Stahl M, Rarey M (2007) Recore: a fast and versatile method for scaffold hopping based on small molecule crystal structure conformations. J Chem Inf Model 47:390-399
56. Bohacek RS, Mc Martin C (1994) Multiple highly diverse structures complementary to enzyme binding sites: results of extensive application of a de novo design method incorporating combinatorial growth. J Am Chem Soc 116:5560-5571
57. Todorov NP, Dean PM (1998) A branch-andbound method for optimal atom-type assignment in de novo ligand design. J Comput Aided Mol Des 12:335-349
58. Todorov NP, Dean PM (1997) Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J Comput Aided Mol Des 11:175-192
59. Lewell XQ, Judd D, Watson S, Hann M (1998) RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 38:511-522
60. Alberts IL, Todorov NP, Dean PM (2005) Receptor flexibility in de novo ligand design and docking. J Med Chem 48:6585-6596
61. Dean PM, Firth-Clark S, Harris W, Kirton SB, Todorov NP (2006) Skel Gen: a general tool for structure-based de novo ligand design. Expert Opin Drug Discov 1:179-189
62. Stahl M, Todorov NP, James T, Mauser H, Boehm H-J, Dean PM (2002) A validation study on the practical use of automated de novo design. J Comput Aided Mol Des 16:459-478
63. Pierce AC, Rao G, Bemis GW (2004) BREED: generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease. J Med Chem 47:2768-2775
64. Schrödinger Release 2014-4: Maestro, version 10.0, (2014) Schrödinger, LLC, New York, NY
65. Molecular Operating Environment (MOE), 2013.08; (2015) Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7
66. Sutherland JJ, Nandigam RK, Erickson JA, Vieth M (2007) Lessons in molecular recognition. Assessing and improving cross-docking accuracy. J Chem Inf Model 47:2293-2302
67. Nandigam RK, Evans DA, Erickson JA, Kim S, Sutherland JJ (2008) Predicting the accuracy of ligand overlay methods with random forest models. J Chem Inf Model 48:2386-2394
68. Erickson JA, Mader MM, Watson IA, Webster YW, Higgs RE, Bell MA, Vieth M (2010) Structure-guided expansion of kinase fragment libraries driven by support vector machine models. Biochim Biophys Acta 1804:642-652
69. Erlanson DA, Mc Dowell RS, O'Brien T (2004) Fragment-based drug discovery. J Med Chem 47:3463-3482
70. de Kloe GE, Bailey D, Leurs R, de Esch IJP (2009) Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today 14:630-646
71. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, Mc Menamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, Saxty G, Seavers LCA, Smith D-M, Squires MS, Trewartha G, Walker MT, Woolford AJA (2008) Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 51:4986-4999
72. Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, Mc Menamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovic M, Wyatt PG (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 52:379-388
73. Antonysamy S, Hirst G, Park F, Sprengeler P, Stappenbeck F, Steensma R, Wilson M, Wong M (2009) Fragment-based discovery of JAK-2 inhibitors. Bioorg Med Chem Lett 19: 279-282
74. Xiang Y, Hirth B, Asmussen G, Biemann H-P, Bishop KA, Good A, Fitzgerald M, Gladysheva T, Jain A, Jancsics K, Liu J, Metz M, Papoulis A, Skerlj R, Stepp JD, Wei RR (2011) The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. Bioorg Med Chem Lett 21:3050-3056
75. Chu MLH, Lang Z, Chavas LMG, Neres J, Fedorova OS, Tabernero L, Cherry M, Williams DH, Douglas KT, Eyers PA (2010) Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes. Biochemistry 49:1689-1701
76. Matthews TP, Klair S, Burns S, Boxall K, Cherry M, Fisher M, Westwood IM, Walton MI, Mc Hardy T, Cheung K-MJ, Van MR, Williams D, Aherne GW, Garrett MD, Reader J, Collins I (2009) Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 52:4810-4819
77. Reader JC, Matthews TP, Klair S, Cheung K-MJ, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, Brandon AH, Box G, Montfort RLM, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I (2011) Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem 54:8328-8342
78. Lainchbury M, Matthews TP, Mc Hardy T, Boxall KJ, Walton MI, Eve PD, Hayes A, Valenti MR, de HBAK, Box G, Aherne GW, Reader JC, Raynaud FI, Eccless SA, Garrett MD, Collins I (2012) Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino) pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem 55: 10229-10240
79. Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu J-Y, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung S-S, Guida WC, Schonbrunn E, Sebti SM (2012) Fragment-based and structure-guided discovery and optimization of rho kinase inhibitors. J Med Chem 55: 2474-2478
80. Irie T, Fujii I, Sawa M (2012) Design and combinatorial synthesis of a novel kinase-focused library using click chemistry-based fragment assembly. Bioorg Med Chem Lett 22:591-596
81. Gentile G, Bernasconi G, Pozzan A, Merlo G, Marzorati P, Bamborough P, Bax B, Bridges A, Brough C, Carter P, Cutler G, Neu M, Takada M (2011) Identification of 2-(4-pyridyl)thienopyridinones as GSK-3β inhibitors. Bioorg Med Chem Lett 21:4823-4827
82. Erlanson DA, Arndt JW, Cancilla MT, Cao K, Elling RA, English N, Friedman J, Hansen SK, Hession C, Joseph I, Kumaravel G, Lee W-C, Lind KE, Mc Dowell RS, Miatkowski K, Nguyen C, Nguyen TB, Park S, Pathan N, Penny DM, Romanowski MJ, Scott D, Silvian L, Simmons RL, Tangonan BT, Yang W, Sun L (2011) Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett 21:3078-3083
83. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KSM, Fong D, Zhu Y-L, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim S-H, Schlessinger J, Zhang KYJ, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041-3046
84. Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10: 811-812